查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1790442

溶小体储积症治疗市场规模、份额和趋势分析报告：按治疗类型、疾病类型、地区和细分市场预测，2025 年至 2033 年

Lysosomal Storage Disease Treatment Market Size, Share & Trends Analysis Report By Treatment Type (Enzyme Replacement Therapy, Substrate Reduction Therapy), By Disease Type, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

溶小体储积症治疗市场摘要

全球溶小体储积症治疗市场规模预计在2024年达到45.4亿美元，预计2025年至2033年期间的复合年增长率为4.54%，到2033年将达到66.8亿美元。这得益于诊断能力的提升、酵素替代疗法和基因疗法的进步以及对罕见遗传疾病认识的提高。溶小体储积症(LSD) 治疗市场正稳定成长，这得益于研发倡议的不断扩展以及对罕见遗传疾病认识的不断提高。

大量的研发投入正在推动治疗方法的进步，并有助于满足尚未满足的医疗需求。美国国家医学图书馆于 2022 年 7 月发表的一项研究发现，LSD 的盛行率比先前认为的更高，总体发生率为 1/5,000 到 1/8,000。该研究也强调了种族和地区对盛行率的影响。例如，在一般人群中，高雪氏症的发生率为 1/40,000 到 1/60,000，但在阿什肯纳兹犹太人中，这一比例上升到 1/800。同样，泰-萨克斯病和 A 型尼曼-匹克病在该族群中很常见，天冬胺酸葡萄糖胺尿症在芬兰人中很常见，发生率为 1/18,500。这些盛行率的上升凸显了对有效治疗方法日益增长的需求，从而推动了市场扩张。

随着创新治疗方法的推出，LSD 治疗市场预计将进一步加强。在全球研发支出不断增加的支持下，各公司都在积极进行开发新药。例如，2021 年 2 月，Genethon 与 Spark Therapeutics 合作，利用其专有技术启动了一项针对迟发性庞贝病的基因治疗临床试验。同时，宣传宣传活动正在获得动力，并在改善患者预后方面发挥关键作用。在美国和英国等国家，透过国家法布瑞氏症基金会 (NFDF)、法布瑞国际网络、澳洲法布瑞氏症和英国MPS 协会推动的每年 4 月的「法布瑞氏症宣传月」等倡议，人们对法布瑞氏症的认识已显着提高。

目录

第一章调查方法与范围

第二章执行摘要

第三章溶小体储积症（LSD）治疗市场变数、趋势与范围

  • 市场体系展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 商业环境分析
    • 产业分析-波特五力分析
    • PESTLE分析
    • 管道分析
    • 专利到期分析
    • 定价分析

第四章溶小体储积症（LSD）治疗市场：依治疗类型分類的业务分析

  • 2025 年和 2033 年治疗类型市场占有率
  • 治疗类型细分仪表板
  • 按治疗类型分類的市场规模、预测和趋势分析（2021-2033 年）
  • 酵素替代疗法
  • 基材还原疗法

第五章溶小体储积症（LSD）治疗市场：依疾病类型分類的业务分析

  • 2025 年及 2033 年各疾病类型的市场占有率
  • 疾病类型细分仪表板
  • 市场规模、预测与趋势分析（按疾病类型，2021-2033 年）
  • 高雪氏症
  • 黏多醣症
  • 庞贝氏症
  • 法布瑞氏症
  • 其他的

第六章溶小体储积症（LSD）治疗市场：区域估计与趋势分析

  • 2025年及2033年区域市场占有率分析
  • 区域市场仪表板
  • 2021-2033 年市场规模与预测趋势分析：
  • 北美洲
    • 按国家/地区，2021-2033 年
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章 竞争态势

  • 参与者概览
  • 企业市场分析
  • 公司分类
  • 战略地图
  • 公司简介/上市公司
    • Pfizer Inc
    • Takeda Pharmaceutical Company Limited（Shire Plc）
    • Sanofi（Genzyme Corporation）
    • BioMarin
    • Johnson &Johnson（Actelion Pharmaceuticals Ltd）
    • Amicus Therapeutics, Inc
    • Alexion Pharmaceuticals, Inc
    • Sigilon Therapeutics, Inc
    • Orphazyme A/S
Product Code: GVR-4-68040-649-3

Lysosomal Storage Disease Treatment Market Summary

The global lysosomal storage disease treatment market size was estimated at USD 4.54 billion in 2024 and is projected to reach USD 6.68 billion by 2033, growing at a CAGR of 4.54% from 2025 to 2033, driven by rising diagnostic capabilities, advancements in enzyme replacement and gene therapies, and increased awareness of rare genetic disorders. The lysosomal storage disease (LSD) treatment market is experiencing steady growth due to expanding research and development initiatives and rising awareness about these rare genetic conditions.

Significant R&D investments have enhanced therapeutic advancements, helping address unmet medical needs. A study published by the National Library of Medicine in July 2022 noted that LSDs, as a group, are more prevalent than previously assumed, with a collective incidence ranging from 1 in 5,000 to 1 in 8,000 individuals. It also highlighted the influence of ethnicity and geography on disease prevalence. For instance, Gaucher disease appears in 1 in 40,000 to 60,000 people in the general population, while the rate increases to 1 in 800 among Ashkenazi Jews. Similarly, Tay-Sachs disease and Niemann-Pick A are more common in this demographic, while the Finnish population has a higher frequency of aspartylglucosaminuria at 1 in 18,500. These rising prevalence rates underscore the growing need for effective treatments, fueling market expansion.

The introduction of innovative therapies is expected to strengthen the LSD treatment market further. Companies actively pursue novel drug development, supported by increasing global R&D spending. For example, in February 2021, Genethon initiated a gene therapy clinical trial targeting late-onset Pompe disease in collaboration with Spark Therapeutics, utilizing proprietary technologies. In parallel, awareness campaigns have gained momentum, playing a vital role in improving patient outcomes. In countries like the U.S. and the UK, awareness of Fabry disease has significantly increased through initiatives like Fabry Disease Awareness Month, observed every April, as promoted by the National Fabry Disease Foundation (NFDF), Fabry International Network, Fabry Australia, and the UK's MPS Society.

Global Lysosomal Storage Disease Treatment Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global lysosomal storage disease treatment market report based on treatment type, disease type, and region:

  • Treatment Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Enzyme Replacement Therapy
    • Velaglucerase Alfa
    • Alglucosidase Alfa (Myozyme/Lumizyme)
    • Idursulfase (Elaprase)
    • Imiglucerase (Cerezyme)
    • Others
  • Substrate Reduction Therapy
  • Others
  • Disease Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Gaucher Disease
  • Mucopolysaccharidoses
  • Pompe Disease
  • Fabry Disease
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Treatment Type
    • 1.2.2. Disease Type
    • 1.2.3. Regional
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Lysosomal Storage Disease (LSDs) Treatment Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Lysosomal Storage Disease (LSDs) Treatment Market: Treatment Type Business Analysis

  • 4.1. Treatment Type Market Share, 2025 & 2033
  • 4.2. Treatment Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Treatment Type, 2021 to 2033 (USD Million)
  • 4.4. Enzyme Replacement Therapy
    • 4.4.1. Enzyme Replacement Therapy Market, 2021 - 2033 (USD Million)
    • 4.4.2. Velaglucerase Alfa
      • 4.4.2.1. Velaglucerase Alfa Market, 2021 - 2033 (USD Million)
    • 4.4.3. Alglucosidase Alfa (Myozyme/Lumizyme)
      • 4.4.3.1. Alglucosidase Alfa (Myozyme/Lumizyme) Market, 2021 - 2033 (USD Million)
    • 4.4.4. Idursulfase (Elaprase)
      • 4.4.4.1. Idursulfase (Elaprase) Market, 2021 - 2033 (USD Million)
    • 4.4.5. Imiglucerase (Cerezyme)
      • 4.4.5.1. Imiglucerase (Cerezyme) Market, 2021 - 2033 (USD Million)
    • 4.4.6. Others
      • 4.4.6.1. Others Market, 2021 - 2033 (USD Million)
  • 4.5. Substrate Reduction Therapy
    • 4.5.1. Substrate Reduction Therapy Market, 2021 - 2033 (USD Million)
    • 4.5.2. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Lysosomal Storage Disease (LSDs) Treatment Market: Disease Type Business Analysis

  • 5.1. Disease Type Market Share, 2025 & 2033
  • 5.2. Disease Type Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Disease Type, 2021 to 2033 (USD Million)
  • 5.4. Gaucher Disease
    • 5.4.1. Gaucher Disease Market, 2021 - 2033 (USD Million)
  • 5.5. Mucopolysaccharidoses
    • 5.5.1. Mucopolysaccharidoses Market, 2021 - 2033 (USD Million)
  • 5.6. Pompe Disease
    • 5.6.1. Pompe Disease Market, 2021 - 2033 (USD Million)
  • 5.7. Fabry Disease
    • 5.7.1. Fabry Disease Market, 2021 - 2033 (USD Million)
  • 5.8. Others
    • 5.8.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Lysosomal Storage Disease (LSDs) Treatment Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2025 & 2033
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 6.4. North America
    • 6.4.1. North America Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Target Disease Type Prevalence
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Reimbursement Framework
      • 6.4.2.5. U.S. Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Target Disease Type Prevalence
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Reimbursement Framework
      • 6.4.3.5. U.S. Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target Disease Type Prevalence
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Reimbursement Framework
      • 6.4.4.5. Mexico Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Target Disease Type Prevalence
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Reimbursement Framework
      • 6.5.2.5. Uk Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Target Disease Type Prevalence
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Reimbursement Framework
      • 6.5.3.5. Germany Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Target Disease Type Prevalence
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. Reimbursement Framework
      • 6.5.4.5. France Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Target Disease Type Prevalence
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. Reimbursement Framework
      • 6.5.5.5. Italy Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Target Disease Type Prevalence
      • 6.5.6.3. Regulatory Framework
      • 6.5.6.4. Reimbursement Framework
      • 6.5.6.5. Spain Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Target Disease Type Prevalence
      • 6.5.7.3. Regulatory Framework
      • 6.5.7.4. Reimbursement Framework
      • 6.5.7.5. Denmark Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Target Disease Type Prevalence
      • 6.5.8.3. Regulatory Framework
      • 6.5.8.4. Reimbursement Framework
      • 6.5.8.5. Sweden Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Target Disease Type Prevalence
      • 6.5.9.3. Regulatory Framework
      • 6.5.9.4. Reimbursement Framework
      • 6.5.9.5. Norway Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Target Disease Type Prevalence
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Reimbursement Framework
      • 6.6.2.5. Japan Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Target Disease Type Prevalence
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Reimbursement Framework
      • 6.6.3.5. China Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Target Disease Type Prevalence
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Reimbursement Framework
      • 6.6.4.5. India Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Target Disease Type Prevalence
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Reimbursement Framework
      • 6.6.5.5. Australia Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Target Disease Type Prevalence
      • 6.6.6.3. Regulatory Framework
      • 6.6.6.4. Reimbursement Framework
      • 6.6.6.5. South Korea Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Target Disease Type Prevalence
      • 6.6.7.3. Regulatory Framework
      • 6.6.7.4. Reimbursement Framework
      • 6.6.7.5. Thailand Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Target Disease Type Prevalence
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. Reimbursement Framework
      • 6.7.2.5. Japan Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Target Disease Type Prevalence
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. Reimbursement Framework
      • 6.7.3.5. China Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2017 - 2033 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Target Disease Type Prevalence
      • 6.8.2.3. Regulatory Framework
      • 6.8.2.4. Reimbursement Framework
      • 6.8.2.5. South Africa Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Target Disease Type Prevalence
      • 6.8.3.3. Regulatory Framework
      • 6.8.3.4. Reimbursement Framework
      • 6.8.3.5. Saudi Arabia Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Target Disease Type Prevalence
      • 6.8.4.3. Regulatory Framework
      • 6.8.4.4. Reimbursement Framework
      • 6.8.4.5. UAE Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Target Disease Type Prevalence
      • 6.8.5.3. Regulatory Framework
      • 6.8.5.4. Reimbursement Framework
      • 6.8.5.5. Kuwait Lysosomal Storage Disease (LSDs) Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Pfizer Inc
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Treatment Type Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Takeda Pharmaceutical Company Limited (Shire Plc)
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Treatment Type Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. Sanofi (Genzyme Corporation)
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Treatment Type Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. BioMarin
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Treatment Type Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Johnson & Johnson (Actelion Pharmaceuticals Ltd)
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Treatment Type Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Amicus Therapeutics, Inc
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Treatment Type Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Alexion Pharmaceuticals, Inc
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Treatment Type Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. Sigilon Therapeutics, Inc
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Treatment Type Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. Orphazyme A/S
      • 7.5.9.1. Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Treatment Type Benchmarking
      • 7.5.9.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global lysosomal storage disease (LSDs) treatment market, by region, 2021 - 2033 (USD Million)
  • Table 4 Global lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 5 Global lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 6 North America lysosomal storage disease (LSDs) treatment market, by country, 2021 - 2033 (USD Million)
  • Table 7 North America lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 8 North America lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 9 U.S. lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 10 U.S. lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 11 Canada lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 12 Canada lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 13 Mexico lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 14 Mexico lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 15 Europe lysosomal storage disease (LSDs) treatment market, by country, 2021 - 2033 (USD Million)
  • Table 16 Europe lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 17 Europe lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 18 UK lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 19 UK lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 20 Germany lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 21 Germany lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 22 France lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 23 France lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 24 Italy lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 25 Italy lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 26 Spain lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 27 Spain lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 28 Norway lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 29 Norway lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 30 Denmark lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 31 Denmark lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 32 Sweden lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 33 Sweden lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 34 Asia Pacific lysosomal storage disease (LSDs) treatment market, by country, 2021 - 2033 (USD Million)
  • Table 35 Asia Pacific lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 36 Asia Pacific lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 37 Japan lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 38 Japan lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 39 China lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 40 China lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 41 India lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 42 India lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 43 Australia lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 44 Australia lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 45 South Korea lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 46 South Korea lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 47 Thailand lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 48 Thailand lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 49 Latin America lysosomal storage disease (LSDs) treatment market, by country, 2021 - 2033 (USD Million)
  • Table 50 Latin America lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 51 Latin America lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 52 Brazil lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 53 Brazil lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 54 Argentina lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 55 Argentina lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 56 Middle East & Africa Lysosomal storage disease (LSDs) treatment market, by country, 2021 - 2033 (USD Million)
  • Table 57 Middle East & Africa lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 58 Middle East & Africa lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 59 South Africa lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 60 South Africa lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 61 Saudi Arabia lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 62 Saudi Arabia lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 63 UAE lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 64 UAE lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)
  • Table 65 Kuwait lysosomal storage disease (LSDs) treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 66 Kuwait lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Lysosomal storage disease (LSDs) treatment market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and disease type outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Lysosomal storage disease (LSDs) treatment market dynamics
  • Fig. 12 Lysosomal storage disease (LSDs) treatment market: Porter's five forces analysis
  • Fig. 13 Lysosomal storage disease (LSDs) treatment market: PESTLE analysis
  • Fig. 14 Treatment Type market, 2021 - 2033 (USD Million)
  • Fig. 15 Enzyme Replacement Therapy market, 2021 - 2033 (USD Million)
  • Fig. 16 Velaglucerase Alfa market, 2021 - 2033 (USD Million)
  • Fig. 17 Alglucosidase Alfa (Myozyme/Lumizyme) market, 2021 - 2033 (USD Million)
  • Fig. 18 Idursulfase (Elaprase) market, 2021 - 2033 (USD Million)
  • Fig. 19 Imiglucerase (Cerezyme) market, 2021 - 2033 (USD Million)
  • Fig. 20 Others market, 2021 - 2033 (USD Million)
  • Fig. 21 Substrate reduction therapy market, 2021 - 2033 (USD Million)
  • Fig. 22 Others market, 2021 - 2033 (USD Million)
  • Fig. 23 Disease Type market, 2021 - 2033 (USD Million)
  • Fig. 24 Gaucher disease market, 2021 - 2033 (USD Million)
  • Fig. 25 Mucopolysaccharidoses market, 2021 - 2033 (USD Million)
  • Fig. 26 Pompe disease market, 2021 - 2033 (USD Million)
  • Fig. 27 Fabry disease market, 2021 - 2033 (USD Million)
  • Fig. 28 Others market, 2021 - 2033 (USD Million)
  • Fig. 29 Lysosomal storage disease (LSDs) treatment market revenue, by region
  • Fig. 30 Regional marketplace: Key takeaways
  • Fig. 31 North America lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 32 U.S. country dynamics
  • Fig. 33 U.S. lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 34 Canada country dynamics
  • Fig. 35 Canada lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 36 Mexico country dynamics
  • Fig. 37 Mexico lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 38 Europe lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 39 UK country dynamics
  • Fig. 40 UK lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 41 Germany country dynamics
  • Fig. 42 Germany lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 43 France country dynamics
  • Fig. 44 France lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 45 Italy country dynamics
  • Fig. 46 Italy lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 47 Spain country dynamics
  • Fig. 48 Spain lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 49 Norway country dynamics
  • Fig. 50 Norway lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 51 Sweden country dynamics
  • Fig. 52 Sweden lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 53 Denmark country dynamics
  • Fig. 54 Denmark lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 55 Asia Pacific lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 56 Japan country dynamics
  • Fig. 57 Japan lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 58 China country dynamics
  • Fig. 59 China lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 60 India country dynamics
  • Fig. 61 India lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 62 Australia country dynamics
  • Fig. 63 Australia lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 64 South Korea country dynamics
  • Fig. 65 South Korea lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 66 Thailand country dynamics
  • Fig. 67 Thailand lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 68 Latin America lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 69 Brazil country dynamics
  • Fig. 70 Brazil lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 71 Argentina country dynamics
  • Fig. 72 Argentina lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 73 MEA lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 74 South Africa country dynamics
  • Fig. 75 South Africa lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 76 Saudi Arabia country dynamics
  • Fig. 77 Saudi Arabia lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 78 UAE country dynamics
  • Fig. 79 UAE lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 80 Kuwait country dynamics
  • Fig. 81 Kuwait lysosomal storage disease (LSDs) treatment market, 2021 - 2033 (USD Million)
  • Fig. 82 Company categorization
  • Fig. 83 Company market position analysis
  • Fig. 84 Strategic framework